Cerebral Vasospasm Market Research Report- Forecast to 2027

Cerebral Vasospasm Market Research Report, by Diagnosis (Computed Tomography Angiography, Digital Subtraction Angiography), Treatment (Nimodipine, Triple-H Therapy, Balloon Angioplasty), End-User (Hospitals, Clinics)– Global Forecast Till 2027

ID: MRFR/MED/0909-HCR | February 2021 | Region: Global | 85 pages

Cerebral Vasospasm Market Scenario


The cerebral vasospasm market is expected to register an approximate CAGR of 5.4% during the forecast period. The narrowing of cerebral arteries is termed as cerebral vasospasm. Cerebral vasospasm is most commonly observed in patients who survive subarachnoid hemorrhage. Narrowing of cerebral artery leads to cerebral ischemia and then death. Increasing prevalence of subarachnoid hemorrhage and a rise in the prevalence of traumatic brain injury is the key factor driving the growth of the market.  According to the Centers for Disease Control and Prevention 2017, 30% of the total injury deaths are due to traumatic brain injury in the US. Other factors contributing to the growth of the market are increasing hypertension among the population, rising adoption of smoking, changing lifestyle, growing geriatric population, increasing prevalence of bleeding disorders, rising use of blood thinners and the introduction of technologically advanced treatments.


However, factors such as high cost associated with treatment, risks associated with drugs and medication and a shortage of skilled professionals are expected to hinder the market growth during the forecast period.


Segmentation


The cerebral vasospasm market is segmented on the basis of diagnosis, treatment, and end-user. The cerebral vasospasm market, by diagnosis, is segmented into CT scan, computed tomography angiography (CTA), digital subtraction angiography (DSA), magnetic resonance angiography (MRA), transcranial Doppler (TCD), and others. The treatment segment is segmented into nimodipine, triple-h therapy, balloon angioplasty, vasopressors, inotropes, thrombolytic agents and anti-inflammatory agents. On the basis of end-users, the cerebral vasospasm market is segmented into hospitals and clinics, ambulatory surgical centers, trauma centers, emergency departments and others.


On the basis of region, the cerebral vasospasm market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players in this market are Headsense Medical Ltd (Israel), B. Braun Melsungen AG (Germany), Minnetronix, Inc (US), Bristol-Myers Squibb Company (US), Boehringer Ingelheim GmbH (Germany) and  H. Lundbeck A/S (Denmark), Actelion Pharmaceuticals Ltd, GE Healthcare, Edge Therapeutics, Inc, SIEMENS AG, Koninklijke Philips N.V, and others.


Regional Market Summary


Cerebral Vasospasm Market Share (%), by Region, 2017


Cerebral Vasospasm Market Share


Sources Centers for Disease Control and Prevention, US Department of Health & Human Services, National Center for Health Statistics, Brain Aneurysm Foundation


The cerebral vasospasm market is dominated by North America owing to the increasing number of traumatic brain injuries in this region. According to the Centers for Disease Control and Prevention, the Traumatic Brain Injury-related Emergency Department visits increased by 47% from 2007 to 2013. Such high incidences of brain traumatic injuries influence market growth. Furthermore, increased adoption of technologically advanced medical implants and the growing healthcare expenditure contribute to enhance the market growth in this region.


It is estimated that Europe was the second largest in the cerebral vasospasm market. Rising health burden due to smoking drives the market in this region. According to the NHS Digital report on Statistics on Smoking,  England, 2018, 484,700 people were hospitalized due to health issues relating to smoking in 2017. This provides favorable backgrounds for the market to grow in this region.  


The cerebral vasospasm market in Asia-Pacific is likely to witness growth owing to the increasing number of elderly people. Brain aneurysms develop after the age of 40 years and are commonly observed in the elderly population. According to the Asian Development Bank (ADB), Asia’s geriatric population is expected to reach 923 million by 2050. This contributes to the positive market growth in this region.


The Middle East and Africa holds the least share in the cerebral vasospasm market due to the presence of stringent government policies and poor economies. However, growing government initiatives, increasing private players investments, and well-equipped healthcare facilities are likely to enhance the market growth in this region.


Market Segmentation and Key Market Players


Cerebral Vasospasm Market, by Diagnosis



  • CT Scan

  • Computed Tomography Angiography (CTA)

  • Digital Subtraction Angiography (DSA)

  • Magnetic Resonance Angiography (MRA)

  • Transcranial Doppler (TCD)


Cerebral Vasospasm Market, by Treatment



  • Nimodipine

  • Triple-H therapy

  • Balloon Angioplasty

  • Vasopressors

  • Inotropes

  • Thrombolytic Agents

  • Anti-inflammatory Agents


Cerebral Vasospasm Market, by End-Users



  • Hospitals and Clinics

  • Ambulatory Surgical Centers

  • Trauma Centers

  • Emergency Departments

  • Others


Cerebral Vasospasm Market, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa


Intended Audience



  • Hospitals

  • Ambulatory centers

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   5.4% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Headsense Medical Ltd (Israel), B. Braun Melsungen AG (Germany), Minnetronix, Inc (US), Bristol-Myers Squibb Company (US), Boehringer Ingelheim GmbH (Germany) and H. Lundbeck A/S (Denmark), Actelion Pharmaceuticals Ltd, GE Healthcare, Edge Therapeutics, Inc, SIEMENS AG, Koninklijke Philips N.V,
  Key Market Opportunities

  • Increasing hypertension among the population
  • Rising adoption of smoking and changing lifestyl
  •   Key Market Drivers

  • Increasing prevalence of subarachnoid hemorrhage
  • Risin prevalence of traumatic brain injury


  • TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Cerebral Vasospasm Market, by Diagnosis

    6.1 Introduction

    6.2 CT scan

    6.3 Computed Tomography Angiography (CTA)

    6.4 Digital Subtraction Angiography (DSA)

    6.5 Magnetic Resonance Angiography (MRA)

    6.6 Transcranial Doppler (TCD)

    Chapter 7. Global Cerebral Vasospasm Market, by Treatment

    7.1 Introduction

    7.2 Nimodipine

    7.3 Triple-H therapy

    7.4 Balloon Angioplasty

    7.5 Vasopressors

    7.6 Inotropes

    7.7 Thrombolytic Agents

    7.8 Anti-inflammatory Agents

    Chapter 8. Global Cerebral Vasospasm Market, by End-Users

    8.1 Introduction

    8.2 Hospitals and Clinics

    8.3 Ambulatory Surgical Centers

    8.4 Trauma Centers

    8.5 Emergency Departments

    8.6 Others

    Chapter 9. Global Cerebral Vasospasm Market, by Region

    9.1 Introduction

    9.2 America

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia-Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia-Pacific

    9.5 Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    Chapter 11 Company Profiles

    11.1 Headsense Medical Ltd

    11.1.1 Company Overview

    11.1.2 Type Overview

    11.1.3 Financials

    11.2.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 B. Braun Melsungen AG

    11.2.1 Company Overview

    11.2.2 Type Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Minnetronix, Inc

    11.3.1 Company Overview

    11.3.2 Type Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Bristol-Myers Squibb Company

    11.4.1 Company Overview

    11.4.2 Type/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Boehringer Ingelheim GmbH

    11.5.1 Company Overview

    11.5.2 Type Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 H. Lundbeck A/S

    11.6.1 Company Overview

    11.6.2 Type Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Koninklijke Philips N.V

    11.7.1 Overview

    11.7.2 Type Overview

    11.7.3 Financials

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 SIEMENS AG

    11.8.1 Overview

    11.8.2 Type Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.9 Edge Therapeutics, Inc.

    11.9.1 Overview

    11.9.2 Type Overview

    11.9.3 Financials

    11.9.4 Key Developments

    11.9.5 SWOT Analysis

    11.10 GE Healthcare

    11.10.1 Overview

    11.10.2 Type Overview

    11.10.3 Financials

    11.10.4 Key Developments

    11.10.5 SWOT Analysis

    11.11 Actelion Pharmaceuticals Ltd.

    11.11.1 Overview

    11.11.2 Type Overview

    11.11.3 Financials

    11.11.4 Key Developments

    11.11.5 SWOT Analysis

    11.12 Others

    Chapter 12 Appendix

    LIST OF TABLES

    Table 1 Global Cerebral Vasospasm Market Industry Synopsis, 2020-2027

    Table 2 Global Cerebral Vasospasm Market Estimates & Forecast, 2020-2027, (USD Million)

    Table 3 Global Cerebral Vasospasm Market, by Region, 2020-2027, (USD Million)

    Table 4 Global Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

    Table 5 Global Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

    Table 6 Global Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

    Table 7 North America: Prescribed Health Apps Market, by Diagnosis, 2020-2027, (USD Million)

    Table 8 North America: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

    Table 9 North America: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

    Table 10 US: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

    Table 11 US: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

    Table 12 US: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

    Table 13 Canada: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

    Table 14 Canada: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

    Table 15 Canada: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

    Table 16 South America: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

    Table 17 South America: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

    Table 18 South America: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

    Table 19 Europe: Cerebral Vasospasm Market, Diagnosis, 2020-2027, (USD Million)

    Table 20 Europe: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

    Table 21 Europe: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

    Table 22 Western Europe: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

    Table 23 Western Europe: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

    Table 24 Western Europe: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

    Table 25 Eastern Europe: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

    Table 26 Eastern Europe: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

    Table 27 Eastern Europe: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

    Table 28 Asia-Pacific: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

    Table 29 Asia-Pacific: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

    Table 30 Asia-Pacific: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

    Table 31 Middle East & Africa: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

    Table 32 Middle East & Africa: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

    Table 33 Middle East & Africa: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for the Global Cerebral Vasospasm Market

    Figure 3 Market Dynamics for the Global Cerebral Vasospasm Market

    Figure 4 Global Cerebral Vasospasm Market Share, by Diagnosis 2020

    Figure 6 Global Cerebral Vasospasm Market Share, by Treatment, 2020

    Figure 6 Global Cerebral Vasospasm Market Share, by End-User, 2020

    Figure 7 Global Cerebral Vasospasm Market Share, by Region, 2020

    Figure 8 North America Cerebral Vasospasm Market Share, by Country, 2020

    Figure 9 Europe Prescribed Health Apps Share, by Country, 2020

    Figure 10 Asia-Pacific Cerebral Vasospasm Market Share, by Country, 2020

    Figure 11 Middle East & Africa Cerebral Vasospasm Market Share, by Country, 2020

    Figure 12 Global Cerebral Vasospasm Market: Company Share Analysis, 2020 (%)

    Figure 13 Headsense Medical Ltd: Key Financials

    Figure 14 Headsense Medical Ltd: Segmental Revenue

    Figure 15 Headsense Medical Ltd: Geographical Revenue

    Figure 16 B. Braun Melsungen AG: Key Financials

    Figure 17 B. Braun Melsungen AG: Segmental Revenue

    Figure 18 B. Braun Melsungen AG: Geographical Revenue

    Figure 19 Minnetronix, Inc: Key Financials

    Figure 20 Minnetronix, Inc: Segmental Revenue

    Figure 21 Minnetronix, Inc: Geographical Revenue

    Figure 22 Bristol-Myers Squibb Company: Key Financials

    Figure 23 Bristol-Myers Squibb Company: Segmental Revenue

    Figure 24 Bristol-Myers Squibb Company: Geographical Revenue

    Figure 25 Boehringer Ingelheim GmbH: Key Financials

    Figure 26 Boehringer Ingelheim GmbH: Segmental Revenue

    Figure 27 Boehringer Ingelheim GmbH: Geographical Revenue

    Figure 28 H. Lundbeck A/S: Key Financials

    Figure 29 H. Lundbeck A/S: Segmental Revenue

    Figure 30 H. Lundbeck A/S: Geographical Revenue

    Figure 31 Koninklijke Philips N.V: Key Financials

    Figure 32 Koninklijke Philips N.V: Segmental Revenue

    Figure 33 Koninklijke Philips N.V: Geographical Revenue

    Figure 34 SIEMENS AG: Key Financials

    Figure 35 SIEMENS AG: Segmental Revenue

    Figure 36 SIEMENS AG: Geographical Revenue

    Figure 37 Edge Therapeutics, Inc.: Key Financials

    Figure 38 Edge Therapeutics, Inc.: Segmental Revenue

    Figure 39 Edge Therapeutics, Inc.: Geographical Revenue

    Figure 40 GE Healthcare: Key Financials

    Figure 41 GE Healthcare: Segmental Revenue

    Figure 42 GE Healthcare: Geographical Revenue

    Figure 43 Actelion Pharmaceuticals Ltd.: Key Financials

    Figure 44 Actelion Pharmaceuticals Ltd.: Segmental Revenue

    Figure 45 Actelion Pharmaceuticals Ltd.: Geographical Revenue